COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Randomized, Placebo-controlled, Double-blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (Nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-positive, Triple-negative Breast Cancer

Protocol No
UC-16-0403-TNBC
Principal Investigator
Sailaja Kamaraju
Phase
II
Summary
The purpose of this study is to find out if a drug called nab-paclitaxel (Abraxane) will respond any better (meaning if your tumor will shrink or stop growing) when given in combination with mifepristone, than if you were receiving nab-paclitaxel and placebo (substance with no active drug). Nab-paclitaxel (Abraxane) is approved by the United States Food and Drug Administration (FDA) to treat breast cancer. Mifepristone is approved by the FDA and is used to terminate pregnancy. Since mifepristone is not approved for use against breast cancer, and the dosing of Abraxane is not being used according to FDA approval, the use of these drugs in this study is considered to be experimental.
Description
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category